BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223805
CREATED:20210809T105337Z
LAST-MODIFIED:20210809T105337Z
UID:31259-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
DESCRIPTION:In the unprecedented array\, and steady stream of novel\, topical\, and systemic agents entering various phases of drug development\, for critical inflammatory and autoimmune dermatological conditions this year\, the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases\, returns to Boston for 2021. As the world’s leading\, and only forum committed to overcoming significant R&D hurdles\, and sharing of best practices for advancing efficacious next generation therapies for chronic inflammatory skin conditions\, this forum is not to be missed. \nWith the rising demand for consolidation and precision medicine\, along with multiple new agents edging closer to market for Atopic Dermatitis towards the end of the year\, the 5th annual meeting addresses advances and challenges in genetic discoveries\, antibody drug development\, delivery strategies and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe\, inflammatory skin conditions. \nEnsure you join this year’s 150+ expert community\, in-person\, to uncover recent studies evaluating critical inflammatory and auto-immune pathways\, gain a deeper understanding of promising biologics targeting IL-13\, IL-31\, IL-33\, whilst continuing to assess emerging efficacious targeted approaches when developing safer treatments to patients with debilitating skin diseases. Additionally\, obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet need such as Hidradenitis Suppurativa and Vitiligo. \nLeave this year’s meeting having overcome innovative modelling challenges by gaining simulation tools/strategies to support your clinical drug development pipeline\, evaluate optimal dose and dosing regimen to support formulation changes for your approach\, whilst having debated what makes a dermatology investment most successful when advancing therapies for inflammatory and autoimmune skin conditions to market. \nTo find out more visit: https://ter.li/e93ads
URL:https://www.pharmajournalist.com/event/5th-annual-dermatology-drug-development-summit-for-inflammatory-skin-diseases/
LOCATION:Hilton Boston/Woburn\, 2 Forbes Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223805
CREATED:20210812T114547Z
LAST-MODIFIED:20210812T114547Z
UID:31287-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:3rd Inflammasome Therapeutics Summit
DESCRIPTION:Discover the Intricacies of Inflammasome Regulation\, Leverage Inflammasome Proteins as Biomarkers & Accelerate Novel Inflammasome Therapeutics into Proof-Of-Concept Clinical Trials & Beyond \nBuilt with Ventus Therapeutics\, Inflammasome Therapeutics\, Merck & more\, the Inflammasome Therapeutics Summit returns for its third year as the only industry-dedicated forum to discover the intricacies of inflammasome regulation and accelerate novel inflammasome therapeutics into proof of-concept clinical trials and beyond! \nWith a plethora of inflammasome-targeted drugs poised to enter the clinic in 2021\, this year’s summit will once again unite thought leaders in inflammasome drug development. \nExpect to be involved in interactive discussions on: \n\nHow dysregulated inflammasome activation\, formation and signaling contributes to disease and how to identify novel drug targets beyond NLRP3\nThe interface of inflammasome signaling with innate immunity\, microbial interactions\, metabolism\, neuroimmune and other systems\nLeveraging inflammasome proteins in precision-based medicine as disease biomarkers and companion diagnostics in both the preclinical and clinical setting\nIdentifying and translating the most promising therapeutic applications of inflammasome-targeted drugs across monogenic diseases\, as well as infectious\, ophthalmic\, neurological and cancer settings\n\nThis year’s meeting has two parallel tracks of learning with 30+ speakers sharing highly anticipated case studies. As the growth potential of novel inflammasome therapeutics becomes apparent\, join the conversation to validate novel inflammasome targets beyond NLRP3 and realize the clinical and commercial potential of inflammasome proteins across different diseases! \nTo Know more visit: https://ter.li/bdw0tf
URL:https://www.pharmajournalist.com/event/3rd-inflammasome-therapeutics-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223805
CREATED:20210903T051305Z
LAST-MODIFIED:20210903T051305Z
UID:31548-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:3rd Exosome Based Therapeutic Development Summit
DESCRIPTION:The 3rd Exosome-Based Therapeutic Development Summit returns with a more comprehensive agenda than ever before\, reuniting leading pharma\, biotech\, technology providers and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine\, autoimmunity\, COVID-19 and beyond. \nDeep diving into the key challenges such as sourcing\, characterization\, cargo loading\, manufacturing and clinical development\, this year’s summit will be your comprehensive roadmap to realizing\, strategizing and advancing the full therapeutics and drug delivery opportunities offered by exosomes. \nTailor-made to showcase the latest innovations and interactively discuss the industry’s most important talking points\, join leading biopharmaceutical Directors\, VPs and C-Level Executives to successfully optimize\, accelerate and scale your exosome-based therapeutics as next generation drugs for unmet clinical needs \nKey Highlights: \n\nShining a spotlight on orally delivered bacterial extracellular vesicles with unique pharmacological profiles with striking anti-inflammatory effects\, an exciting new approach for exosome therapeutics with Evelo Biosciences\n\n\nDeep dive into the latest data coming out of the clinic with key learnings from phase I/II trials of Covid-19\, oesteoarthirtus and gastrointestinal diseases with insights from Organicell\, University of Athens & University of Louisville\n\n\nNavigating the complex regulatory landscape for exosomes to understand what the FDA requires to progress through each development stage and the potential for successful applications into 2021 with insights from Rion\n\n\nExploring proteomic insights in understanding EVs and the mechanisms of action of EV-mediated RNA delivery to enable more efficient and efficacious exosome therapies with Exogenus Therapeutics Aruna Bio\, Stem XO & Baker Heart and Diabetes Institute\n\n\nExpanding the boundaries of engineering exosomes including cell selection\, applications of the technology\, monitoring biodistribution and enabling direct delivery with Exogenus VivaZome Therapeutics\, OmniSpriant & Exogenus Therapeutics\n\nTo know more visit: https://ter.li/h99vsb
URL:https://www.pharmajournalist.com/event/3rd-exosome-based-therapeutic-development-summit/
LOCATION:Digital Event\, EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211117
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223805
CREATED:20210628T103640Z
LAST-MODIFIED:20210628T103640Z
UID:30747-1637107200-1637279999@www.pharmajournalist.com
SUMMARY:Wnt & β-Catenin Targeted Drug Discovery Summit
DESCRIPTION:The Wnt & β-Catenin Targeted Drug Discovery Summit is the only meeting uniting leading pharma\, pioneering biotechs and reputed academics under a mutual and ambitious objective of accelerating your novel Wnt/β-catenin candidates into clinic and market. \nBuilt with Leap Therapeutics\, Fog Pharma\, Surrozen\, Iterion Therapeutics\, Genentech\, and other leading companies\, the summit will allow you to gain knowledge on the inhibition and activation of the Wnt pathway. You can be sure to take away practical insights and actionable strategies on how to harness this previously undruggable target. \nWith 24+ expert speakers\, this is your definitive opportunity to be a part of this exciting and growing community\, and this dedicated virtual summit will ensure you get your answers to your questions. \nTo find out more and view the 2021 speaker line-up\, download the full event guide. \n \n5 unmissable keynotes include: \n\nSupercharging Your Wnt/β-catenin Clinical Program by Surrozen\, Iterion Therapeutics\, AntlarA & Leap Therapeutics\nGetting a Grip on Wnt Biology to Theorize the Latest Opportunities & Understandings with Iterion Therapeutics\, Genentech & Auburn University\nOpportunities to Aid Drug Discovery & Further Research Efforts with Biovista & the DTRF\nDelving into Immuno-Oncology to Further Oncological Treatment Efficacy\, brought to you by UAB\, Duke Cancer Institute & Shandong First Medical University\nHarnessing Novel Pathways Approach to Drive Preclinical Insights delivered by\nFog Pharma\, RedX Pharma & The University of Oxford\n\nTo know more about the Wnt & β-Catenin Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/wnt-%ce%b2-catenin-targeted-drug-discovery-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211117
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223805
CREATED:20210708T095717Z
LAST-MODIFIED:20210708T095717Z
UID:30858-1637107200-1637279999@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Gut Therapeutics USA
DESCRIPTION:Microbiome Connect: Gut Therapeutics USA\, a two-day conference from the 17th – 18th of November 2021 and will bring you essential solutions to the challenges you face in the microbiome field. This industry-leading event will facilitate discussions concerning new clinical research\, microbiome biomarkers\, the latest regulatory developments\, gut-organ axis\, human clinical updates and much more. Hear from experts like Bernat Olle\, CEO of Vedanta Bioscience\, regarding the state of the market post-C Diff. therapy approval\, and Diwakar Davar\, to discuss his ground-breaking immuno-oncology research. \n \nThe event will have dedicated manufacturing steam; attendees will witness a showcase of solutions to scaling up your bacterial fermentation operation\, highlighting the different culturing methodologies along with discussions regarding commercialization preparation. Joined by companies such as Takeda\, Merck\, and PRI\, who will discuss the microbiome’s clinical future as a diagnostic and endpoint and examine how the industry can and should develop standardized biomarkers. Leading biotechs will discuss their latest clinical updates\, mechanistic data\, experimental methods\, and clinical trial design. \nMicrobiome Connect will be hosting their annual skin and oral event at the same venue and dates\, which all gut attendees will have access to. Download the agenda https://hubs.ly/H0RQsBQ0.
URL:https://www.pharmajournalist.com/event/microbiome-connect-gut-therapeutics-usa/
LOCATION:275 Tremont St\, Boston\, MA 02116\, United States\, MA\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211117
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223805
CREATED:20210715T094233Z
LAST-MODIFIED:20210726T202001Z
UID:30944-1637107200-1637279999@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Oral USA
DESCRIPTION:The Oral Microbiome is the second largest and diverse microbiota in the human body\, harboring over 700 species of bacteria. A complex and constantly changing habitat\, it is crucial in maintaining not only oral health and oral diseases\, but systemic health conditions across the body. To date\, over 50 systemic diseases have been linked to an unbalanced oral microbiome\, and research in this space is accelerating. Further developing a collective understanding of the role of the oral microbiome in health and disease will allow further developments in drug development\, oral health\, and targeted therapies in the future. \nJoin us at the 6th Annual Microbiome Connect to discover the latest research relating to the oral microbiome\, and its critical and underappreciated role in human health. Be a part of the discussion surrounding pre- and pro-biotics\, innovative therapies. \nFind out more >>> https://hubs.ly/H0T0d430
URL:https://www.pharmajournalist.com/event/microbiome-connect-oral-usa/
LOCATION:Join the Microbiome Connect community at the picturesque Courtyard by Marriott\, Boston Downtown Boutique Hotel\, 275 Tremont St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211117
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T223805
CREATED:20210901T074913Z
LAST-MODIFIED:20210901T075014Z
UID:31528-1637107200-1637279999@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Skin USA
DESCRIPTION:Love the skin you’re in? How about the bugs on it? \nOver the six years we’ve run Microbiome Connect: Skin\, the field has changed drastically. In a short period\, the field has gone from fringe to mainstream\, from quantifying the size of bacterial populations to understanding their function. As the field continues to commercialize\, it is time to ask how this research can benefit consumers. How can the skin microbiome be leveraged as a source of biomarkers\, as a therapeutic modality\, as an understandable term to consumers? \nJoin us in Boston for a two-day face-to-face event\, attended in the past by the likes of P&G\, Jackson Laboratory\, and the FDA. Unravel the function of the skin microbiome and apply the latest findings to your future products. See you in November! \nTo know more visit: https://hubs.ly/H0W7lQ90
URL:https://www.pharmajournalist.com/event/microbiome-connect-skin-usa/
LOCATION:Boston\, MA\, USA
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR